{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
First approved in 2011
Class:
STRUCTURALLY DIVERSE
Status:
First approved in 2011
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:enekinragene inzadenovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:cretostimogene grenadenorepvec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:opilrelagene atradenorepvec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:delolimogene mupadenorepvec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:tezemlimogene daxadenorepvec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:encoberminogene rezmadenovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:alferminogene tadenovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03190824: Phase 2 Interventional Active, not recruiting Melanoma Stage III
(2016)
Source URL:
Class:
STRUCTURALLY DIVERSE